Compare SD & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SD | VOGX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 475.4M |
| IPO Year | 2006 | 2026 |
| Metric | SD | VOGX |
|---|---|---|
| Price | $14.63 | $32.71 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 251.6K | 210.1K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 12.43 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.10 | $14.80 |
| 52 Week High | $18.45 | $35.50 |
| Indicator | SD | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 78.35 |
| Support Level | $14.37 | $27.37 |
| Resistance Level | $15.71 | $35.06 |
| Average True Range (ATR) | 0.33 | 4.36 |
| MACD | 0.05 | -0.42 |
| Stochastic Oscillator | 71.14 | 52.68 |
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.